Figure 2.
Therapy with anti-CD47 antibody SRF231 induces durable responses in TCL PDX and murine models in vivo. (A-F) Tumor burden and organ weights of mice engrafted with the HSTCL PDX DFTL-81777 and treated with hIgG4 isotype control or anti-CD47 antibody. (G-N) Tumor burden in blood and BM (n = 3 per antibody group). *P < .05; **P < .01; ***P < .001, ****P < .0001 by 2-sided Welch t test. Kaplan-Meier survival analyses (n = 3-6 per antibody group) by log-rank test. Arrows indicate start (day 0) and stop (day 10 for models 81777 and 22685) and start (day 0) and stop (day 4 for model 85005) of treatment. (O) Kaplan-Meier survival analysis of ITK-SYK xenograft model treated with murine anti-CD47 antibody, MIAP410, or with mIgG1κ isotype control, MOPC-21 (n = 3 per antibody group) log-rank test. BM, bone marrow.

Therapy with anti-CD47 antibody SRF231 induces durable responses in TCL PDX and murine models in vivo. (A-F) Tumor burden and organ weights of mice engrafted with the HSTCL PDX DFTL-81777 and treated with hIgG4 isotype control or anti-CD47 antibody. (G-N) Tumor burden in blood and BM (n = 3 per antibody group). *P < .05; **P < .01; ***P < .001, ****P < .0001 by 2-sided Welch t test. Kaplan-Meier survival analyses (n = 3-6 per antibody group) by log-rank test. Arrows indicate start (day 0) and stop (day 10 for models 81777 and 22685) and start (day 0) and stop (day 4 for model 85005) of treatment. (O) Kaplan-Meier survival analysis of ITK-SYK xenograft model treated with murine anti-CD47 antibody, MIAP410, or with mIgG1κ isotype control, MOPC-21 (n = 3 per antibody group) log-rank test. BM, bone marrow.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal